For the second quarter of fiscal year 2023, ARBUTUS BIOPHARMA ($NASDAQ:ABUS) reported a total revenue of USD 4.7 million, a decrease of 67.3% from the same period in the previous year. Net income for this quarter was USD -17.1 million, lower than the -14.2 million reported in the same quarter of the previous year.
ARBUTUS BIOPHARMA reported its second quarter fiscal year 2023 earnings results on Thursday. The stock opened the day at $2.1 and continued to remain at that price, ending the day with a closing price of $2.1. This represents a 1.0% decrease from the prior day’s closing price of 2.1.
The company has expressed confidence in the continued growth of its business in the coming quarters and expects to see further success and improved results as it continues to expand its operations. Furthermore, ARBUTUS BIOPHARMA has stated that it will continue to invest heavily in research and development, as well as other initiatives that will help it further its mission to create innovative healthcare solutions and provide quality patient care. Live Quote…
About the Company
Ownership (Institutional/ Fund Holdings)
Below shows the total revenue, net income and net margin for Arbutus Biopharma. More…
Income Statement Reports (Yearly/ Quarterly/ LTM)
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for Arbutus Biopharma. More…
Cash Flow Statement (Yearly/ Quarterly/ LTM)
Cash Flow Supplement
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for Arbutus Biopharma. More…
Balance Sheet (Yearly/ Quarterly)
Balance Sheet Supplement
||Book Value Per Share
Key Ratios Snapshot
Some of the financial key ratios for Arbutus Biopharma are shown below. More…
Income Statement Ratios
Balance Sheet Ratios
Cash Flow Ratios
Other Supplementary Items
|3Y Rev Growth
||3Y Operating Profit Growth
At GoodWhale, we have examined the financials of ARBUTUS BIOPHARMA and our analysis reveals that the company has a low health score of 3/10 according to its Star Chart. This indicates that the company is less likely to ride out any potential crisis without the risk of bankruptcy. Our system also concludes that ARBUTUS BIOPHARMA is classified as a ‘rhino’, meaning that the company has achieved moderate revenue or earnings growth. Given its strong asset base, medium growth, and weak dividend and profitability, we believe that investors who are looking to make long-term investments in a relatively stable company may be interested in ARBUTUS BIOPHARMA. They may also be attracted to the potential for moderate growth over time. Regardless, investors should be aware of the low health score and factors that could contribute to an increased risk of bankruptcy. More…
Risk Rating Analysis
Star Chart Analysis
The biotech industry is competitive, and Arbutus Biopharma Corp is no exception. The company competes with Assembly Biosciences Inc, Moderna Inc, and Vaccitech PLC, among others. While each company has its own strengths and weaknesses, Arbutus Biopharma Corp has a strong track record of success.
– Assembly Biosciences Inc ($NASDAQ:ASMB)
Founded in 2013, Assembly Biosciences Inc is a clinical-stage biotechnology company that discovers, develops, and commercializes novel drugs to treat patients with infectious diseases and liver diseases. The company’s most advanced product candidate is ABI-729, which is in Phase 2 clinical trials for the treatment of chronic hepatitis B virus infection. The company has a market cap of 65.37M as of 2022 and a Return on Equity of -51.01%.
Moderna Inc is a biotechnology company that focuses on the development of vaccines and therapeutics. As of 2022, Moderna Inc has a market cap of 65.77B and a return on equity of 46.4%. The company’s market cap is based on the current share price of its stock and the total number of shares outstanding. Moderna Inc’s return on equity is a measure of its profitability and is calculated by dividing its net income by its shareholders’ equity.
Vaccitech PLC is a clinical stage immunology company. The company has a market cap of 86.15M as of 2022 and a return on equity of -0.79%. The company’s main focus is the development of therapeutic vaccines to treat and prevent cancer and infectious diseases.
Arbutus Biopharma has reported their earnings results for Q2 2023, with total revenue of USD 4.7 million, a decrease of 67.3% year-over-year. Net income also decreased to USD -17.1 million from the previous year’s figure of -14.2 million. Investing in Arbutus Biopharma is a risky prospect as their performance has been declining over the last quarter.
Their revenue has dropped significantly and their net income has moved further into negative territory, which are both concerning indicators. Further developments should be monitored before investing in this company.